Using Cenobamate for managing idiopathic generalized epilepsy: A single‐center experience and systematic literature review
Epilepsia Open · 2025-12 · 10 (6) · 1871-1882
DOI: 10.1002/epi4.70157 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Epilepsia Open, online erschienen am 07.10.2025. Verfasst von Nicole Woodrich und 4 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Epilepsy, Generalized, Anticonvulsants, Carbamates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To evaluate the single‐center experience of Cenobamate's (CNB) off‐label use in adults with idiopathic generalized epilepsy (IGE).
Methods
We conducted a retrospective review of electronic health records within a large healthcare system to identify IGE patients prescribed CNB. Extensive clinical and medication‐related data were extracted, including monthly seizure frequency at baseline, 3, 6, and 12 months, and at last follow‐up. We used CNB retention, a marker of its potential effectiveness and tolerability, for 12 months as the primary outcome of interest. Statistical analysis, including Kaplan–Meier survival analysis, was performed to estimate CNB retention over time. We also performed a systematic literature review investigating seizure reduction after CNB use in IGE.
Results
Sixteen IGE patients (median age = 36 years; 11 females) treated with CNB were included. Twelve (75%) had JME. Median epilepsy duration was 18 years, and a median of 8 ASMs were tried before CNB use. Among the 14 patients with at least a 12‐month follow‐up, 8 (57%) achieved the primary outcome. Median CNB retention based on survival analysis was 34 months, and 31% of patients stopped CNB within 3 months. At 3, 6, and 12 months, ≥50% seizure reduction was seen in 75%, 86%, and 63% of patients, respectively. Of 8 patients on CNB at last follow‐up (median CNB use of 21 months), 3 (38%) were seizure‐free. Median ER visits declined significantly in the 6 months post‐CNB ( p = 0.028; Cohen's d = 0.66). Fatigue, dizziness, and cognitive symptoms were the most frequently reported adverse effects. Systematic review revealed 3 articles with 4 IGE patients whose seizure outcomes were similar to our findings. Significance The study found CNB's use in IGE to be effective, including decreased ER visits. These findings provide preliminary evidence to suggest that off‐label use of CNB can be considered in drug‐resistant IGE patients. Plain Language Summary Cenobamate (CNB), an anti‐seizure medicine, was studied for off‐label use in 16 adults with drug‐resistant idiopathic generalized epilepsy (IGE). Most had juvenile myoclonic epilepsy and long‐standing seizures despite many prior treatments. Over half continued CNB for at least 12 months, and around 30% stopped within 3 months. At 3, 6, and 12 months, 63%–86% had at least 50% fewer seizures; three patients became seizure‐free. Emergency visits dropped significantly after starting CNB. Common side effects were fatigue, dizziness, and cognitive issues. These findings suggest CNB can help reduce seizures and healthcare use in adults with difficult‐to‐treat IGE, warranting further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Nicole Woodrich, Andreas Alexopoulos, Dileep Nair, Imad M Najm, Vineet Punia
Zitieren
APA
Woodrich, N., Alexopoulos, A., Nair, D., Najm, I. M., & Punia, V. (2025). Using Cenobamate for managing idiopathic generalized epilepsy: A single‐center experience and systematic literature review. Epilepsia Open, 10(6), 1871-1882. https://doi.org/10.1002/epi4.70157
Vancouver
Woodrich N, Alexopoulos A, Nair D, Najm IM, Punia V. Using Cenobamate for managing idiopathic generalized epilepsy: A single‐center experience and systematic literature review. Epilepsia Open. 2025;10(6):1871-1882. doi:10.1002/epi4.70157
BibTeX
@article{Woodrich2025,
author = {Woodrich, Nicole and Alexopoulos, Andreas and Nair, Dileep and Najm, Imad M and Punia, Vineet},
title = {Using Cenobamate for managing idiopathic generalized epilepsy: A single‐center experience and systematic literature review},
journal = {Epilepsia Open},
year = {2025},
volume = {10},
number = {6},
pages = {1871--1882},
doi = {10.1002/epi4.70157}
}
EUVIMED